Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
{{output}}
ONTARGET has established the efficacy of the angiotensin receptor blocker (ARB) telmisartan to slow disease progression and delay or prevent morbid events in patients with atherosclerosis. Although the study failed to confirm additive efficacy of telmisartan a... ...
